BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Employees

580

Sector

Biotechnology & Medical Research

Calendar

Jul. 30 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-06-20	9.950 $	-0.10%	1,226,225
25-06-18	9.960 $	-0.10%	3,071,287
25-06-17	9.970 $	-3.11%	3,895,400
25-06-16	10.29 $	-0.77%	2,910,829
25-06-13	10.37 $	-0.29%	2,661,229

Delayed Quote Nasdaq, June 18, 2025 at 03:59 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.960USD

Average target price

16.58USD

Spread / Average Target

+66.50%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 12:07:12 2025-06-20 pm EDT			5-day change	1st Jan Change
9.915 ^USD	-0.45%		-4.00%	+32.38%

Jun. 16	BioCryst Pharmaceuticals, Inc. Announces Retirement of George B. Abercrombie as A Member of the Board's Audit Committee, Commercialization Committee, and Corporate Governance and Nominating Committee, Effective June 12, 2025	CI
Jun. 16	Biocryst Pharmaceuticals, Inc. Presents New Data on the Long-Term Efficacy and Safety of Orladeyo®? (Berotralstat) Across All Ages At Eaaci	CI

Capitalization	2.08B 1.82B 1.71B 1.55B 2.86B 181B 3.23B 20.14B 7.78B 82.47B 7.82B 7.65B 304B	P/E ratio 2025 *	75.2x	P/E ratio 2026 *	28.4x
Enterprise value	2.24B 1.95B 1.83B 1.67B 3.08B 195B 3.47B 21.65B 8.36B 88.62B 8.4B 8.23B 326B	EV / Sales 2025 *	3.65x	EV / Sales 2026 *	2.74x
Free-Float	97%	Yield 2025 *	-	Yield 2026 *	-

BioCryst Pharmaceuticals, Inc. Announces Retirement of George B. Abercrombie as A Member of the Board's Audit Committee, Commercialization Committee, and Corporate Governance and Nominating Committee, Effective June 12, 2025	Jun. 16	CI
Biocryst Pharmaceuticals, Inc. Presents New Data on the Long-Term Efficacy and Safety of Orladeyo®? (Berotralstat) Across All Ages At Eaaci	Jun. 16	CI
Sector Update: Health Care Stocks Lean Lower Premarket Friday	Jun. 13	MT
BioCryst Pharmaceuticals, Inc. Announces National Institute of Drug and Food Surveillance Grants Approval for Oral, Once-Daily ORLADEYO	Jun. 13	CI
BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia	Jun. 13	MT
BioCryst Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:40 AM	Jun. 09
Sector Update: Health Care Stocks Advance Premarket Friday	Jun. 06	MT
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Approved for Reimbursement in Netherlands	Jun. 06	MT
BioCryst Achieves Reimbursement for ORLADEYO Across All Major European Countries	Jun. 06	CI
BioCryst Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 04:55 PM	Jun. 04
BioCryst Pharmaceuticals, Inc. to Present New Data At 2025 Meeting of the European Academy of Allergy and Clinical Immunology	Jun. 02	CI
BioCryst Pharmaceuticals, Inc. Highlights Real-World Data Showing ORLADEYO®? (berotralstat) Consistently Reduces HAE Attacks Across All Ages	May. 30	CI
BioCryst Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03:05 PM	May. 21

RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating	May. 06	MT
RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating	Feb. 25	MT
JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	24-05-07	MT
BioCryst Pharmaceuticals Receives Upgrade From RBC to Outperform From Sector Perform, Price Target Raised to $10 From $9	23-09-18	MT
Jefferies Upgrades BioCryst Pharmaceuticals to Buy From Hold, Price Target is $11	23-08-04	MT

BioCryst Pharmaceuticals, Inc. Stock

Equities

BCRX

US09058V1035

Biotechnology & Medical Research

Valuation: BioCryst Pharmaceuticals, Inc.

Chart: BioCryst Pharmaceuticals, Inc.

Latest news: BioCryst Pharmaceuticals, Inc.

Last Transcript: BioCryst Pharmaceuticals, Inc.

Analysts' recommendations: BioCryst Pharmaceuticals, Inc.

Press Releases: BioCryst Pharmaceuticals, Inc.

News in other languages: BioCryst Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: BioCryst Pharmaceuticals, Inc.

ETFs: BioCryst Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO across all Ages at EAACI	Jun. 17	AQ
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI	Jun. 16	AQ
ORLADEYO® (berotralstat) Approved in Colombia	Jun. 13	AQ
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries	Jun. 06	AQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jun. 03	AQ

BioCryst et l’Alliance pharmaceutique pancanadienne concluent avec succès les négociations au sujet de ORLADEYO (bérotralstat), un traitement oral à prise uniquotidienne pour la prévention des crises d’angio-œdème héréditaire	24-09-17
Koersalarm: aandeel Pharvaris blijft stijgen	23-12-07
L’INESSS recommande le remboursement public pour ORLADEYO® (bérotralstat) de BioCryst pour la prévention des crises chez les patients atteints d’angio-oedème héréditaire au Québec	23-09-18
BioCryst Pharmaceuticals : La valeur du jour à Wall Street - BIOCRYST : Ebola sème le trouble aux Etats-Unis	14-10-01
BioCryst Pharmaceuticals : Les biotechs dopées par l'arrivée d'Ebola aux Etats-Unus	14-10-01

1 day	-0.05%
1 week	-4.18%
Current month	-7.30%
1 month	-3.91%
3 months	+30.60%
6 months	+34.84%
Current year	+32.51%

1 week	9.84	10.46
1 month	9.84	11.31
Current year	6.02	11.31
1 year	6	11.31
3 years	4.03	15.43
5 years	3.3	19.99
10 years	1.38	19.99

Manager	Title	Age	Since
Jon Stonehouse CEO	Chief Executive Officer	64	2006-12-31
Helen Thackray CTO	Chief Tech/Sci/R&D Officer	56	2021-03-18
Salisa Hauptmann LAW	General Counsel	-	2020-12-31

Director	Title	Age	Since
Jon Stonehouse BRD	Director/Board Member	64	2006-12-31
Nancy Hutson CHM	Chairman	75	2023-03-30
Theresa Heggie BRD	Director/Board Member	64	2018-12-02

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BIOCRYST PHARMACEUTICALS, INC.	-0.05%	-4.18%	+66.08%	+3.59%	2.08B
REGENERON PHARMACEUTICALS, INC.	+0.89%	-1.62%	-50.59%	-11.63%	54.27B
ARGENX SE	+0.42%	-5.45%	+32.48%	+45.86%	33.13B
WUXI APPTEC CO., LTD.	-1.17%	-4.11%	+54.82%	-32.36%	25.88B
BIONTECH SE	-0.43%	-0.38%	+21.15%	-16.48%	25.71B
INSMED INCORPORATED	-0.82%	+2.66%	+51.66%	+435.31%	18.89B
SUMMIT THERAPEUTICS INC.	+1.46%	-0.10%	+153.65%	+1,954.89%	14.97B
GENMAB A/S	+0.30%	-5.20%	-21.87%	-30.63%	13.28B
WUXI BIOLOGICS (CAYMAN) INC.	-0.41%	-14.29%	+104.78%	-64.55%	12.49B
EXELIXIS, INC.	-1.45%	-2.45%	+89.03%	+119.59%	11.11B
Average	-0.12%	-3.53%	+50.12%	+240.36%	21.18B
Weighted average by Cap.	+0.05%	-2.90%	+26.98%	+175.83%

	2025 *	2026 *
Net sales	614M 535M 503M 457M 843M 53.31B 951M 5.93B 2.29B 24.29B 2.3B 2.25B 89.46B	698M 609M 572M 520M 959M 60.66B 1.08B 6.75B 2.61B 27.63B 2.62B 2.56B 102B
Net income	30.21M 26.34M 24.75M 22.5M 41.5M 2.62B 46.81M 292M 113M 1.2B 113M 111M 4.4B	91.48M 79.77M 74.93M 68.14M 126M 7.95B 142M 884M 341M 3.62B 343M 336M 13.33B
Net Debt	156M 136M 127M 116M 214M 13.51B 241M 1.5B 580M 6.16B 584M 571M 22.67B	-173M -151M -142M -129M -238M -15.06B -269M -1.68B -647M -6.86B -651M -637M -25.28B